Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities.
Identifieur interne : 000965 ( Main/Exploration ); précédent : 000964; suivant : 000966Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities.
Auteurs : Nancy A. Risebrough [Canada] ; Susan K. Bowles ; Andrew E. Simor ; Alison Mcgeer ; Paul I. OhSource :
- Journal of the American Geriatrics Society [ 0002-8614 ] ; 2005.
Descripteurs français
- KwdFr :
- Acétamides (usage thérapeutique), Acétamides (économie), Amantadine (usage thérapeutique), Amantadine (économie), Analyse coût-bénéfice (MeSH), Antiviraux (usage thérapeutique), Antiviraux (économie), Canada (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (économie), Humains (MeSH), Maisons de repos (économie), Modèles économiques (MeSH), Oséltamivir (MeSH), Soins de longue durée (économie), Sujet âgé (MeSH), Techniques d'aide à la décision (MeSH), Épidémies de maladies (prévention et contrôle), Épidémies de maladies (économie).
- MESH :
- prévention et contrôle : Grippe humaine, Épidémies de maladies.
- usage thérapeutique : Acétamides, Amantadine, Antiviraux.
- économie : Acétamides, Amantadine, Antiviraux, Grippe humaine, Maisons de repos, Soins de longue durée, Épidémies de maladies.
- Analyse coût-bénéfice, Canada, Humains, Modèles économiques, Oséltamivir, Sujet âgé, Techniques d'aide à la décision.
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- Acetamides (economics), Acetamides (therapeutic use), Aged (MeSH), Amantadine (economics), Amantadine (therapeutic use), Antiviral Agents (economics), Antiviral Agents (therapeutic use), Canada (MeSH), Cost-Benefit Analysis (MeSH), Decision Support Techniques (MeSH), Disease Outbreaks (economics), Disease Outbreaks (prevention & control), Humans (MeSH), Influenza, Human (economics), Influenza, Human (prevention & control), Long-Term Care (economics), Models, Economic (MeSH), Nursing Homes (economics), Oseltamivir (MeSH).
- MESH :
- chemical , economics : Acetamides, Amantadine, Antiviral Agents.
- chemical , therapeutic use : Acetamides, Amantadine, Antiviral Agents.
- geographic : Canada, Oseltamivir.
- economics : Disease Outbreaks, Influenza, Human, Long-Term Care, Nursing Homes.
- prevention & control : Disease Outbreaks, Influenza, Human.
- Aged, Cost-Benefit Analysis, Decision Support Techniques, Humans, Models, Economic.
Abstract
OBJECTIVES
To compare the cost-effectiveness of oseltamivir postexposure prophylaxis during influenza A outbreaks with that of amantadine postexposure prophylaxis or no postexposure prophylaxis in long-term care facilities (LTCFs).
DESIGN
Cost-effectiveness analysis based on decision analytic model from a government-payer perspective.
SETTING
A Canadian LTCF, with high staff vaccination, at the beginning of influenza season.
PARTICIPANTS
Elderly, influenza-vaccinated patients living in a Canadian LTCF.
MEASUREMENTS
Incremental costs (or savings) per influenza-like illness case avoided compared with usual care.
RESULTS
From a government-payer perspective, this analysis showed that oseltamivir was a dominant strategy because it was associated with the fewest influenza-like illness cases, with cost savings of $1,249 per 100 patients in 2001 Canadian dollars compared with amantadine and $3,357 per 100 patients compared with no prophylaxis. Costs for amantadine dose calculation and hospitalization for adverse events contributed to amantadine being a more-expensive prophylaxis strategy than oseltamivir. Both prophylaxis strategies were more cost-effective than no prophylaxis.
CONCLUSION
Despite high influenza vaccination rates, influenza outbreaks continue to emerge in LTCFs, necessitating cost-effective measures to further limit the spread of influenza and related complications. Although amantadine has a lower acquisition cost than oseltamivir, it is associated with more adverse events, lower efficacy, and individualized dosing requirements, leading to higher overall costs and more influenza-like illness cases than oseltamivir. Therefore the use of oseltamivir postexposure prophylaxis is more cost-effective than the current standard of care with amantadine prophylaxis or no prophylaxis.
DOI: 10.1111/j.1532-5415.2005.53162.x
PubMed: 15743287
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities.</title><author><name sortKey="Risebrough, Nancy A" sort="Risebrough, Nancy A" uniqKey="Risebrough N" first="Nancy A" last="Risebrough">Nancy A. Risebrough</name><affiliation wicri:level="3"><nlm:affiliation>Health Outcomes and PharmacoEconomics Research Center, Sunnybrook and Women's College Health Sciences Centre, Toronto, Canada. nancy.risenbrough@sw.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Health Outcomes and PharmacoEconomics Research Center, Sunnybrook and Women's College Health Sciences Centre, Toronto</wicri:regionArea><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Bowles, Susan K" sort="Bowles, Susan K" uniqKey="Bowles S" first="Susan K" last="Bowles">Susan K. Bowles</name></author><author><name sortKey="Simor, Andrew E" sort="Simor, Andrew E" uniqKey="Simor A" first="Andrew E" last="Simor">Andrew E. Simor</name></author><author><name sortKey="Mcgeer, Alison" sort="Mcgeer, Alison" uniqKey="Mcgeer A" first="Alison" last="Mcgeer">Alison Mcgeer</name></author><author><name sortKey="Oh, Paul I" sort="Oh, Paul I" uniqKey="Oh P" first="Paul I" last="Oh">Paul I. Oh</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15743287</idno><idno type="pmid">15743287</idno><idno type="doi">10.1111/j.1532-5415.2005.53162.x</idno><idno type="wicri:Area/Main/Corpus">000966</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000966</idno><idno type="wicri:Area/Main/Curation">000966</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000966</idno><idno type="wicri:Area/Main/Exploration">000966</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities.</title><author><name sortKey="Risebrough, Nancy A" sort="Risebrough, Nancy A" uniqKey="Risebrough N" first="Nancy A" last="Risebrough">Nancy A. Risebrough</name><affiliation wicri:level="3"><nlm:affiliation>Health Outcomes and PharmacoEconomics Research Center, Sunnybrook and Women's College Health Sciences Centre, Toronto, Canada. nancy.risenbrough@sw.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Health Outcomes and PharmacoEconomics Research Center, Sunnybrook and Women's College Health Sciences Centre, Toronto</wicri:regionArea><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Bowles, Susan K" sort="Bowles, Susan K" uniqKey="Bowles S" first="Susan K" last="Bowles">Susan K. Bowles</name></author><author><name sortKey="Simor, Andrew E" sort="Simor, Andrew E" uniqKey="Simor A" first="Andrew E" last="Simor">Andrew E. Simor</name></author><author><name sortKey="Mcgeer, Alison" sort="Mcgeer, Alison" uniqKey="Mcgeer A" first="Alison" last="Mcgeer">Alison Mcgeer</name></author><author><name sortKey="Oh, Paul I" sort="Oh, Paul I" uniqKey="Oh P" first="Paul I" last="Oh">Paul I. Oh</name></author></analytic><series><title level="j">Journal of the American Geriatrics Society</title><idno type="ISSN">0002-8614</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetamides (economics)</term><term>Acetamides (therapeutic use)</term><term>Aged (MeSH)</term><term>Amantadine (economics)</term><term>Amantadine (therapeutic use)</term><term>Antiviral Agents (economics)</term><term>Antiviral Agents (therapeutic use)</term><term>Canada (MeSH)</term><term>Cost-Benefit Analysis (MeSH)</term><term>Decision Support Techniques (MeSH)</term><term>Disease Outbreaks (economics)</term><term>Disease Outbreaks (prevention & control)</term><term>Humans (MeSH)</term><term>Influenza, Human (economics)</term><term>Influenza, Human (prevention & control)</term><term>Long-Term Care (economics)</term><term>Models, Economic (MeSH)</term><term>Nursing Homes (economics)</term><term>Oseltamivir (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acétamides (usage thérapeutique)</term><term>Acétamides (économie)</term><term>Amantadine (usage thérapeutique)</term><term>Amantadine (économie)</term><term>Analyse coût-bénéfice (MeSH)</term><term>Antiviraux (usage thérapeutique)</term><term>Antiviraux (économie)</term><term>Canada (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (économie)</term><term>Humains (MeSH)</term><term>Maisons de repos (économie)</term><term>Modèles économiques (MeSH)</term><term>Oséltamivir (MeSH)</term><term>Soins de longue durée (économie)</term><term>Sujet âgé (MeSH)</term><term>Techniques d'aide à la décision (MeSH)</term><term>Épidémies de maladies (prévention et contrôle)</term><term>Épidémies de maladies (économie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Acetamides</term><term>Amantadine</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acetamides</term><term>Amantadine</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term><term>Long-Term Care</term><term>Nursing Homes</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term><term>Épidémies de maladies</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acétamides</term><term>Amantadine</term><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Acétamides</term><term>Amantadine</term><term>Antiviraux</term><term>Grippe humaine</term><term>Maisons de repos</term><term>Soins de longue durée</term><term>Épidémies de maladies</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cost-Benefit Analysis</term><term>Decision Support Techniques</term><term>Humans</term><term>Models, Economic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Canada</term><term>Humains</term><term>Modèles économiques</term><term>Oséltamivir</term><term>Sujet âgé</term><term>Techniques d'aide à la décision</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>To compare the cost-effectiveness of oseltamivir postexposure prophylaxis during influenza A outbreaks with that of amantadine postexposure prophylaxis or no postexposure prophylaxis in long-term care facilities (LTCFs).</p></div><div type="abstract" xml:lang="en"><p><b>DESIGN</b></p><p>Cost-effectiveness analysis based on decision analytic model from a government-payer perspective.</p></div><div type="abstract" xml:lang="en"><p><b>SETTING</b></p><p>A Canadian LTCF, with high staff vaccination, at the beginning of influenza season.</p></div><div type="abstract" xml:lang="en"><p><b>PARTICIPANTS</b></p><p>Elderly, influenza-vaccinated patients living in a Canadian LTCF.</p></div><div type="abstract" xml:lang="en"><p><b>MEASUREMENTS</b></p><p>Incremental costs (or savings) per influenza-like illness case avoided compared with usual care.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>From a government-payer perspective, this analysis showed that oseltamivir was a dominant strategy because it was associated with the fewest influenza-like illness cases, with cost savings of $1,249 per 100 patients in 2001 Canadian dollars compared with amantadine and $3,357 per 100 patients compared with no prophylaxis. Costs for amantadine dose calculation and hospitalization for adverse events contributed to amantadine being a more-expensive prophylaxis strategy than oseltamivir. Both prophylaxis strategies were more cost-effective than no prophylaxis.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Despite high influenza vaccination rates, influenza outbreaks continue to emerge in LTCFs, necessitating cost-effective measures to further limit the spread of influenza and related complications. Although amantadine has a lower acquisition cost than oseltamivir, it is associated with more adverse events, lower efficacy, and individualized dosing requirements, leading to higher overall costs and more influenza-like illness cases than oseltamivir. Therefore the use of oseltamivir postexposure prophylaxis is more cost-effective than the current standard of care with amantadine prophylaxis or no prophylaxis.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15743287</PMID><DateCompleted><Year>2005</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-8614</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><Issue>3</Issue><PubDate><Year>2005</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of the American Geriatrics Society</Title><ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation></Journal><ArticleTitle>Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities.</ArticleTitle><Pagination><MedlinePgn>444-51</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To compare the cost-effectiveness of oseltamivir postexposure prophylaxis during influenza A outbreaks with that of amantadine postexposure prophylaxis or no postexposure prophylaxis in long-term care facilities (LTCFs).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cost-effectiveness analysis based on decision analytic model from a government-payer perspective.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">A Canadian LTCF, with high staff vaccination, at the beginning of influenza season.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Elderly, influenza-vaccinated patients living in a Canadian LTCF.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Incremental costs (or savings) per influenza-like illness case avoided compared with usual care.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">From a government-payer perspective, this analysis showed that oseltamivir was a dominant strategy because it was associated with the fewest influenza-like illness cases, with cost savings of $1,249 per 100 patients in 2001 Canadian dollars compared with amantadine and $3,357 per 100 patients compared with no prophylaxis. Costs for amantadine dose calculation and hospitalization for adverse events contributed to amantadine being a more-expensive prophylaxis strategy than oseltamivir. Both prophylaxis strategies were more cost-effective than no prophylaxis.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Despite high influenza vaccination rates, influenza outbreaks continue to emerge in LTCFs, necessitating cost-effective measures to further limit the spread of influenza and related complications. Although amantadine has a lower acquisition cost than oseltamivir, it is associated with more adverse events, lower efficacy, and individualized dosing requirements, leading to higher overall costs and more influenza-like illness cases than oseltamivir. Therefore the use of oseltamivir postexposure prophylaxis is more cost-effective than the current standard of care with amantadine prophylaxis or no prophylaxis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Risebrough</LastName><ForeName>Nancy A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Health Outcomes and PharmacoEconomics Research Center, Sunnybrook and Women's College Health Sciences Centre, Toronto, Canada. nancy.risenbrough@sw.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowles</LastName><ForeName>Susan K</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>Simor</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>McGeer</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Paul I</ForeName><Initials>PI</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Geriatr Soc</MedlineTA><NlmUniqueID>7503062</NlmUniqueID><ISSNLinking>0002-8614</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000081">Acetamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>BF4C9Z1J53</RegistryNumber><NameOfSubstance UI="D000547">Amantadine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000081" MajorTopicYN="N">Acetamides</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000547" MajorTopicYN="N">Amantadine</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003661" MajorTopicYN="N">Decision Support Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018803" MajorTopicYN="Y">Models, Economic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15743287</ArticleId><ArticleId IdType="pii">JGS53162</ArticleId><ArticleId IdType="doi">10.1111/j.1532-5415.2005.53162.x</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement></list><tree><noCountry><name sortKey="Bowles, Susan K" sort="Bowles, Susan K" uniqKey="Bowles S" first="Susan K" last="Bowles">Susan K. Bowles</name><name sortKey="Mcgeer, Alison" sort="Mcgeer, Alison" uniqKey="Mcgeer A" first="Alison" last="Mcgeer">Alison Mcgeer</name><name sortKey="Oh, Paul I" sort="Oh, Paul I" uniqKey="Oh P" first="Paul I" last="Oh">Paul I. Oh</name><name sortKey="Simor, Andrew E" sort="Simor, Andrew E" uniqKey="Simor A" first="Andrew E" last="Simor">Andrew E. Simor</name></noCountry><country name="Canada"><region name="Ontario"><name sortKey="Risebrough, Nancy A" sort="Risebrough, Nancy A" uniqKey="Risebrough N" first="Nancy A" last="Risebrough">Nancy A. Risebrough</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000965 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000965 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeCanadaV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:15743287
|texte= Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:15743287" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV4
| This area was generated with Dilib version V0.6.35. |  |